Sahlmann CO - Search Results

Year	Number of Results
2002	2
2003	2
2004	2
2005	2
2006	2
2007	2
2009	1
2010	2
2011	2
2012	4
2013	5
2014	2
2015	6
2016	5
2017	2
2018	4
2019	5
2020	1
2021	2
2022	7
2023	1
2024	0

1

Brain ¹⁸ F-FDG-PET and an optimized cingulate island ratio to differentiate Lewy body dementia and Alzheimer's disease.

Woyk K, Sahlmann CO, Hansen N, Timäus C, Müller SJ, Khadhraoui E, Wiltfang J, Lange C, Bouter C. Woyk K, et al. Among authors: sahlmann co. J Neuroimaging. 2023 Mar;33(2):256-268. doi: 10.1111/jon.13068. Epub 2022 Dec 12. J Neuroimaging. 2023. PMID: 36465027

2

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review.

Lisney AR, Leitsmann C, Strauß A, Meller B, Bucerius JA, Sahlmann CO. Lisney AR, et al. Among authors: sahlmann co. Cancers (Basel). 2022 Jul 26;14(15):3638. doi: 10.3390/cancers14153638. Cancers (Basel). 2022. PMID: 35892897 Free PMC article. Review.

3

Correction: Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.

Schmidt M, Bartenstein P, Bucerius J, Dietlein M, Drzezga A, Herrmann K, Lapa C, Lorenz K, Musholt TJ, Nagarajah J, Reiners C, Sahlmann CO, Kreissl MC. Schmidt M, et al. Among authors: sahlmann co. Nuklearmedizin. 2022 Apr 27. doi: 10.1055/a-1824-1280. Online ahead of print. Nuklearmedizin. 2022. PMID: 35477170 English. No abstract available.

4

Ansprechen eines metastasierten akrolentiginösen Melanoms mit Exon-11-BRAF-G469A-Mutation auf BRAF/MEK-Inhibition.

Julius K, Kromer C, Schnabel V, Vlahova L, Kitz J, Schön MP, Sahlmann CO, Kretschmer L. Julius K, et al. Among authors: sahlmann co. J Dtsch Dermatol Ges. 2022 Apr;20(4):527-529. doi: 10.1111/ddg.14737_g. J Dtsch Dermatol Ges. 2022. PMID: 35446501 No abstract available.

5

Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.

Schmidt M, Bartenstein P, Bucerius J, Dietlein M, Drzezga A, Herrmann K, Lapa C, Lorenz K, Musholt TJ, Nagarajah J, Reiners C, Sahlmann CO, Kreissl MC. Schmidt M, et al. Among authors: sahlmann co. Nuklearmedizin. 2022 Apr;61(2):87-96. doi: 10.1055/a-1783-8154. Epub 2022 Mar 17. Nuklearmedizin. 2022. PMID: 35299276 Free article. English, German.

6

Response of metastatic acral melanoma with exon 11 BRAF G469A mutation to BRAF/MEK inhibition.

Julius K, Kromer C, Schnabel V, Vlahova L, Kitz J, Schön MP, Sahlmann CO, Kretschmer L. Julius K, et al. Among authors: sahlmann co. J Dtsch Dermatol Ges. 2022 Apr;20(4):528-530. doi: 10.1111/ddg.14737. Epub 2022 Feb 26. J Dtsch Dermatol Ges. 2022. PMID: 35218304 No abstract available.

7

Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging.

Modemann DJ, Mahardhika AB, Yamoune S, Kreyenschmidt AK, Maaß F, Kremers S, Breunig C, Sahlmann CO, Bucerius J, Stalke D, Wiltfang J, Bouter Y, Müller CE, Bouter C, Meller B. Modemann DJ, et al. Among authors: sahlmann co. Eur J Med Chem. 2022 Mar 15;232:114138. doi: 10.1016/j.ejmech.2022.114138. Epub 2022 Jan 28. Eur J Med Chem. 2022. PMID: 35193075

8

Liver Enzyme Elevation After ¹⁷⁷Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer.

Treiber H, König A, Neesse A, Richter A, Sahlmann CO, Strauss A. Treiber H, et al. Among authors: sahlmann co. J Nucl Med. 2021 Jul 1;62(7):1016-1019. doi: 10.2967/jnumed.120.258533. Epub 2021 May 14. J Nucl Med. 2021. PMID: 33990402 Free article.

9

Mesorectal Lymph Node Metastases as Index Lesion in ⁶⁸Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer.

Leitsmann C, Schmid M, Sahlmann CO, Trojan L, Strauss A. Leitsmann C, et al. Among authors: sahlmann co. Front Surg. 2021 Mar 1;8:637134. doi: 10.3389/fsurg.2021.637134. eCollection 2021. Front Surg. 2021. PMID: 33732729 Free PMC article.

10

[Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].

König F, Strauß A, Johannsen M, Mommsen C, Fricke E, Klier J, Mehl S, Pfister D, Sahlmann CO, Werner A, Goebell PJ. König F, et al. Among authors: sahlmann co. Urologe A. 2020 Jan;59(1):53-64. doi: 10.1007/s00120-019-01052-4. Urologe A. 2020. PMID: 31598745 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

53 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year